Post on 03-Jun-2020
transcript
1
Introduction to Quantium Health Outcomes
Joshila Shiba
July 2019
2
01 Introduction to Quantium
02 Introduction to Quantium Health Outcomes
03 South African Medical Device Market
04 Real World Evidence – how do we improve patient outcomes
3
Commercial in confidence Our 16 year history assures best practice in privacy and security
•We have built our business based on privacy by design principles for the past 16 years
•No personal information is ever received or held by Quantium
• All information is de-identified using an irreversible tokenisation process with no ability to re-identify individuals
•We apply a higher test than the Privacy Act
•We are GDPR ready
•We use ‘bank grade’ security to store and process our data
•Comply with 200+ security requirements from NAB, Woolworths and other partners
• All partner data is held in a separate restricted environment
• All access to partner data is limited to essential staff only
• Security environment and processes regularly audited by NAB and other data partners
Privacy Security
Quantium believes in using data for progress, with great care and responsibility, as such please respect the commercial in confidence natureof this presentation
We all have a responsibility to use data for good –to power breakthrough possibilities for individuals, organisations and society
4
Introduction to Quantium
01
5
Actuaries
Statisticians
Data Scientists
Product Leaders
Strategy Consultants
Software Engineers
Delivery Managers
Industry Experts
Designers
Futurists
A diverse team:
Hyderabad
Johannesburg
San Francisco
Founded in 2002 in Australia, we have a global team with a unique blend of analytics capabilities
Auckland
Brisbane
Sydney (HQ)
Melbourne
750+Quantium people
9 Offices worldwide, headquartered in Sydney
Bentonville
London
6
Our history
Quantium opens for business
Data partnership
Data partnership and transaction
Media partnership
Mediapartnership
Datapartnership
Mediapartnership
Mediapartnership
Health joint venture
Media partnerships
OC
T 2
00
2
AP
R 2
00
9
MA
Y 2
01
3
MA
Y 2
01
4
AP
R 2
01
5
MA
R 2
01
6
OC
T 2
01
6
OC
T 2
01
7
JU
L 2
01
5
MA
R 2
01
5
MA
R 2
01
4
DE
C 2
01
7
Banking Partnership
7
We work with iconic brands in over 20 countries, partnering on their greatest challenges and unlocking transformational opportunities through:
Government & HealthTop 5 MediaTop 10 Insurers 7 of top 10 Retailers Top 15 CPG Top 10 PropertyTop 5 Banks
Telco Industrial Sport & Culture Airline/Gambling TechnologyCharity Gaming
8
We bring expertise in two core domains to develop cutting-edge solutions for a ‘big data world’
Data Science
We translate raw data into actionable insight
Data cleansing and curation
Data ecosystem
Data monetisation
Applied analytics
Artificial Intelligence
We build transformative data-powered solutions
Decision support tools
Decision engines
Machine learning
9
10
A word from one of our clients
At Walmart, we are always looking at ways to accelerate innovation for the benefit of our customers.
Quantium has developed a world-class data science and AI solution that has transformed the accuracy of Walmart’s prediction of customers’ needs at scale. The solution determines what our customers need, when and where they need it, significantly reducing both stock-outs and wastage.
Quantium’s people combine technical excellence with incisive commerciality. They took the time to really understand Walmart and delivered a solution that has yielded an immediate improvement in customer experience, along with financial benefits at both the cost and revenue lines.
Greg ForanPresident and CEO, Walmart US
11
02
Introduction to Quantium Health Outcomes
12
Quantium Health Outcomes combines data and analytics with medical expertise
Industrial strength analyticsLargest data analytics company in Australia
New innovative productsProven ability to create new innovative products in the industries it works in
Technology platformTop 3 data processing capacity outside of government in Australia
Data ecosystemAbility to combine data from multiple organisations in a privacy compliant way. Ability to integrate publicly available data from ABS or AEC
Quantium Health Outcomes is a joint venture that combines the analytical IP and data assets of Quantium, the health and wellnessIP within Discovery, and the clinical expertise and implementation of Health Outcomes Australia
Recognised global leader in utilising health dataLargest health insurer in South Africa. Bespoke health classifications and tools including patient complexity tools, clinical and economic health technology evaluation and proprietary data assets
Deployment of health tools and assetsExtensive experience in deploying health data tools and assets in value based procurement, disease management and clinical policy development
Health data 5 million lives including health, life insurance and lifestyle data
Woolworths10m loyalty cardholders, trillions of items purchased
NAB2.5m customers, over 4 billion transactions
Foxtel2.8m households, every click on the remote control since January 2014
Media partnerships with Facebook, Google, News Corp, Woolworths and oOh! Media
Access to the data from Quantium’s data partners
Quantium PartnersCapability in health
Quantium Health Outcomes
Recognised leader in supporting clinicians and patients to measure and understand health outcomesHOA work with clinicians and patients, with government and corporations to collect health outcomes data, understand its implications and act to lead positive change
Experienced leaders in clinical integrationExtensive experience in working with health providers to integrate new findings into best practice
13
2bn Data
records
40% Private Market
10 YrsLongitudinal
data
3.6m Insured lives
Quantium Health Outcomes has developed the most comprehensive Global Medical Device Nomenclature Database (GMDN) in South Africa . Currently over 50
000 medical device products are mapped to a GMDN code. GMDN provides for a first time , an international standard for identifying all medical
devices at a generic level in a meaningful manner that can be understood by all users.
Vitality Wellness
Data
14
03
South African Medical Device Market
15
South African Medical Device Market 2018
R12bnTotal Spend
3% YoY Growth overall
1017# Competitors
#ProductCategories
168
16
Web based self service insight portal for the medical device market. Provide access to market insights across product portfolios.Helps businesses drive strategies across products,regions,providers and treatment areas. Q.Checkup provides a 360 view of your market performance to help you understand how best to grow your business
Product Overview Product Snapshot
Breakdown by product category, provider, location and medical condition
Allows the creation of specific sales forces data and monitoring performance
Providing 5 years sales and market share trends
Data is up to date and refreshed monthly
9
34
55
0 10 20 30 40 50 60
DILATATION CATHETERS/BALLOONS
WOUND MANAGEMENT
STENTS AND GRAFTS
Number of new nappi codes
New Product Launches
New Market Reports – Gain insight into the market performance of specific product categories to understand market potential and price points, allowing for strategically planned market entry
17
18
Representation and use cases
ResultsClients have generated tangible benefits: e.g. targeted remediation of market losses, market entry no-go’s, strengthened funder negotiations
RepresentationOur clients represent R7.5bn of annual total private market spend
Clients25 of the largest suppliers make use of our tools and analytical consulting services
19
Our services have been used across several disease areas in South Africa
20
Our data enables businesses to drive success
In the medical space in SA it was always hard to reallyjudge where we stand in terms of market share andperformance of our business and products in the market.All our estimates would be based on guesses and with noreal informed data. Your platform and data provide uswith eye opening information on where to take ourbusiness. Not only has the information changed the waywe approach our product segmentation but also a totalnew approach to our business.
Nico CoetzeeCEO, Essilor South Africa
To date the marketing environment in our industry had nodata to support our assumptions. We could only build ourmarketing models based on knowledge gained from thefield. The Quantium toolkit provides us with immediateaccess to our business and market share information.This assists us with our sales management to monitorthe performance in each region.
Q.CheckUp userNational Sales and Marketing Manager
In a market where we historically had to make a lot ofassumptions it is of tremendous help to now have anopportunity to check and confirm assumptions made.This tool assists me to optimise my resources and planon future growth strategies and have more realisticgrowth expectations not just per product but also perterritory.
Q.CheckUp userBusiness Unit Director
QHO is one of the few companies that take the time tolisten to your concerns surrounding the outcomes oftheir analysis. They are willing to look at the datadifferently to answer all questions. Open communication,knowledge sharing and adaptability are key attributesfrom the analytics team and part of their success.
Charmaine Timm-MilliganHead: Strategic Planning & Business Development
Roche Products
21
04
Real world evidence – how do we improve patient outcomes
22
Example 1: Health Outcomes Measures
Retrospective study of patients receiving PCI with different Drug Eluting Stents
1. Compare clinical outcomes - Major adverse cardiac events
2. Compare downstream cost implications
Using real-world data, determine the downstream costs of complications associated with each option
Aggregate initial and downstream costs to demonstrate superior long-term economical outcomes
Application in medical devices- Drug Eluting Stents
Drug No-MACE MACE Total Percentage
DES Stent 1 2058 193 2251 8.6%
DES Stent 2 2333 196 2529 7.8%
DES Stent 3 1867 149 2016 7.4%
Grand Total 2781 4015 6796 7.9%
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
0-1
9
40
-59
10
0-1
19
14
0-1
59
18
0-1
99
22
0-2
39
28
0-2
99
32
0-3
39
36
0-3
79
40
0-4
19
46
0-4
79
50
0-5
19
56
0-5
79
62
0-6
39
70
0-7
19
74
0-7
59
78
0-7
99
10
20
-10
39
Per
cen
tage
of
Dea
ths
Number of days post-procedure
Stent A Stent B Stent C
23
Example 2: Measuring clinical outcomes of comparable treatments
Motivate for the use of safer catheterisation products in specific populations
Using real-world data, determine the infection rates in patients using each device type
Demonstrate differences in rates of infection between the treatment options available
Use results to educate providers and patients in their choice of catheterisation products
Application in treatment risks
0%
2%
4%
6%
0 1 2 3 4 5 6 7 8 9 10 11
UT
I p
ati
en
ts
Months since catheterisation commenement
Percentage of patients developing UTIs
Single-use catheters Reusable catheters
24
Example 3: Measuring downstream costs of comparable devices
Motivate for the necessity of enhanced material in implantable ocular device
Using real-world data, determine the downstream costs of complications associated with each option
Aggregate initial and downstream costs to demonstrate superior long-term economical outcomes
Use results to educate providers and inform payer discussions
Application in medical devices
0
500
1 000
1 500
2 000
0 12 24 36 48
Co
st
pe
r e
ye (
R)
Months since device implant
Cummulative downstream costs of complication A per eye
Client's enhanced product Competitors' enhanced products Competitors' standard products
-
10 000
20 000
30 000
40 000
Alcon- Hydrophobic Competitor- Hydrophilic Competitor- Hydrophobic
Ave
rag
e c
os
t (R
)
Total 48-month cost outcomes by product
Device Complication A Complication B Complication C Consultation Medication
Client
25
Disclaimer: This report comprises, and is the subject of intellectual property (including copyright) and confidentiality rights of one or multiple owners, including The Quantium Group Pty Limited (Quantium) and where applicable,its third-party data owners (Data Providers), together (IP Owners). The information contained in this report may have been prepared using raw data owned by the Data Providers. The Data Providers have not been involved in theanalysis of the raw data, the preparation of, or the information contained in the report. The IP Owners do not make any representation (express or implied), nor give any guarantee or warranty in relation to the accuracy,completeness or appropriateness of the raw data, nor the analysis contained in this report. None of the IP Owners will have any liability for any use or disclosure by the recipient of any information contained in, or derived fromthis report. To the maximum extent permitted by law, the IP Owners expressly disclaim, take no responsibility for and have no liability for the preparation, contents, accuracy or completeness of this report, nor the analysis onwhich it is based. This report is provided in confidence, may only be used for the purpose provided, and may not be copied, reproduced, distributed, disclosed or made available to a third party in any away except strictly inaccordance with the applicable written terms and conditions between you and Quantium, or otherwise with Quantium’s prior written permission.
Thank you